GlassScriptPhysician profile
Gary C Carlson
NPI 1497700116
$11,373.50
in general payments reported to CMS, 2019-2025
55 companies · $1,727 in 2025
The $1,727 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,620 · 2020: $1,333 · 2021: $1,746 · 2022: $1,791 · 2023: $1,623 · 2024: $1,534 · 2025: $1,727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,884.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,883.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,462.28 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $1,235.68 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $1,154.92 | 2019-2025 | Ubrelvy, Synthroid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $888.99 | 2019-2025 | Jardiance, Ofev, Spiriva Respimat |
| Pfizer INC. | $817.72 | 2019-2025 | |
| Amgen INC. | $758.24 | 2019-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $624.94 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $574.97 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $555.02 | 2019-2025 | Capvaxive, Verquvo, Belsomra |
| Janssen Pharmaceuticals, INC | $463.44 | 2019-2024 | Xarelto |
| Exact Sciences Corporation | $212.07 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $207.73 | 2021-2024 | Freestyle Libre 3 |
| Astellas Pharma US INC | $206.33 | 2019-2023 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $194.03 | 2019-2025 | Shingrix, Arexvy |
| Kowa Pharmaceuticals America, INC. | $174.06 | 2019-2025 | Zoryve |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Carlson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.